✦ LIBER ✦

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

✍ Scribed by Schroth, W.; Goetz, M. P.; Hamann, U.; Fasching, P. A.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V. J.; Ames, M. M.

Book ID: 111942255
Publisher: American Medical Association
Year: 2009
Tongue: English
Weight: 418 KB
Volume: 302
Category: Article
ISSN: 0098-7484
DOI: 10.1001/jama.2009.1420

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Association between Genetic Polymorphism

Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment

✍ Park, Hyung Seok; Choi, Ji-Yeob; Lee, Mi-Jeong; Park, Seho; Yeo, Chang-Woo; Lee, 📂 Article 📅 2011 🏛 Korean Academy of Medical Sciences 🌐 English ⚖ 573 KB

Comprehensive CYP2D6 genotype and adhere

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

✍ Alastair M. Thompson; Andrea Johnson; Philip Quinlan; Grantland Hillman; Marcel 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 321 KB

Effectiveness of Adjuvant Tamoxifen Ther

Effectiveness of Adjuvant Tamoxifen Therapy among Older Women with Early Stage Breast Cancer

✍ Cynthia Owusu; Timothy L. Lash; Rebecca A. Silliman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 538 KB

Lack of any association between function

Lack of any association between functionally significantCYP2D6polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment

✍ In Hae Park; Jungsil Ro; Sohee Park; Hyeong-Seok Lim; Keun Seok Lee; Han Sung Ka 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 333 KB

Risk of early recurrence among postmenop

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen

✍ Hagen Kennecke; Heather McArthur; Ivo A. Olivotto; Caroline Speers; Chris Bajdik 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

## Abstract ## BACKGROUND Adjuvant aromatase inhibitors (AIs), instead of or after tamoxifen, are effective in decreasing recurrence in postmenopausal women with estrogen receptor (ER)‐positive breast cancer. An understanding of which patients are at risk of early recurrence while they are receivi

Excellent outcomes with adjuvant toremif

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer

✍ Jaime D. Lewis; Anees B. Chagpar; Elizabeth A. Shaughnessy; Jacob Nurko; Kelly M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract ## BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. We hypothesized that toremifene as compared with tamoxifen given as adjuvant therapy for early stage breast cancer wo